Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NAL1866 (octreotide)
- Development stage
- Preclinical
- Lead developer
- Nal Pharmaceuticals
- Modality
- Peptides
- Administration
- Intramuscular, Subcutaneous
01
Overview
NAL1866 is a sustained-release microsphere formulation of octreotide acetate, a synthetic octapeptide analogue of endogenous somatostatin, developed by NAL Pharmaceutical Group. Octreotide acts as a potent agonist at somatostatin receptors (SSTRs), particularly subtypes SSTR2 and SSTR5, mimicking the natural hormone's inhibitory effects on the secretion of growth hormone, glucagon, insulin, and various gastrointestinal peptides. The NAL1866 asset utilizes a microsphere delivery system designed for injectable administration to provide prolonged therapeutic effect, primarily targeting supportive oncology indications such as the management of symptoms associated with metastatic carcinoid tumors and vasoactive intestinal peptide-secreting tumors (VIPomas). It is currently in preclinical development.
- Other names
- octreotide acetate
02
Targets
SSTR2 (Somatostatin receptor type 2)SSTR3 (Somatostatin receptor 3)SSTR5 (Somatostatin receptor 5)SSTR (Somatostatin receptors)
Beyond the preview
Go deeper on NAL1866 (octreotide).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NAL1866 (octreotide).